While funding for insurtech companies has generally declined in Q1 2024, sector stakeholders suggest it is more of a balancing out than a cause for concern. Joel Albarella, Head of NYL Ventures, the venture capital arm of New York Life Insurance Company, described it as a “healthy reset” that will benefit the industry broadly.